Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders

被引：14
|
作者：
Yoon, David S. [1 ]
Wu, Shung C. [1 ]
Seethala, Ramakrishna [2 ]
Golla, Rajasree [2 ]
Nayeem, Akbar [3 ]
Everlof, John G. [4 ]
Gordon, David A. [5 ]
Hamann, Lawrence G. [1 ]
Robl, Jeffrey A. [1 ]
机构：
[1] Bristol Myers Squibb Co, Res & Dev, Dept Chem, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb Co, Res & Dev, Lead Evaluat, Princeton, NJ 08543 USA
[3] Bristol Myers Squibb Co, Res & Dev, CADD, Princeton, NJ 08543 USA
[4] Bristol Myers Squibb Co, Res & Dev, PCO Discovery Pharmaceut, Princeton, NJ 08543 USA
[5] Bristol Myers Squibb Co, Res & Dev, Dept Biol, Princeton, NJ 08543 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 21期
关键词：
11-Beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1); Enzyme inhibitor; Pyridyl sulfonamide; Type-2; diabetes; SELECTIVE INHIBITORS; VISCERAL OBESITY; POTENT; HYPERGLYCEMIA; DESIGN; MODEL; MICE;
D O I：
10.1016/j.bmcl.2014.09.012
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A previous disclosure from this lab highlighted the discovery of pyridyl amides as potent 11 beta-HSD1 inhibitors. In order to build additional novelty and polarity into this chemotype, replacement of the hydrogen-bonding carbonyl (CO) pharmacophore with the bioisosteric sulfonyl (SO2) group was examined. Despite initial comparisons suggesting the corresponding sulfonamides exhibited weaker activity versus their carbonyl counterparts, further optimization was performed in an effort to identify various potent and unique leads for the program. Judicious incorporation of polar moieties resulted in the identification of compounds with enhanced potency and lipophilicity profiles, resulting in leads with superior aqueous solubility and liver microsomal stability. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5045 / 5049
页数：5
相关论文
共 50 条
  • [31] Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1
    Tice, Colin M.
    Zhao, Wei
    Krosky, Paula M.
    Kruk, Barbara A.
    Berbaum, Jennifer
    Johnson, Judith A.
    Bukhtiyarov, Yuri
    Panemangalore, Reshma
    Scott, Boyd B.
    Zhao, Yi
    Bruno, Joseph G.
    Howard, Lamont
    Togias, Jennifer
    Ye, Yuan-Jie
    Singh, Suresh B.
    McKeever, Brian M.
    Lindblom, Peter R.
    Guo, Joan
    Guo, Rong
    Nar, Herbert
    Schuler-Metz, Annette
    Gregg, Richard E.
    Leftheris, Katerina
    Harrison, Richard K.
    McGeehan, Gerard M.
    Zhuang, Linghang
    Claremon, David A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (22) : 6725 - 6729
  • [32] The discovery of azepane sulfonamides as potent 11β-HSD1 inhibitors
    Neelamkavil, Santhosh F.
    Boyle, Craig D.
    Chackalamannil, Samuel
    Greenlee, William J.
    Zhang, Lili
    Terracina, Giuseppe
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (16) : 4563 - 4565
  • [33] Functional Effects of Polymorphisms in the Human Gene Encoding 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1): A Sequence Variant at the Translation Start of 11β-HSD1 Alters Enzyme Levels
    Malavasi, Elise L. V.
    Kelly, Val
    Nath, Nikita
    Gambineri, Alessandra
    Dakin, Rachel S.
    Pagotto, Uberto
    Pasquali, Renato
    Walker, Brian R.
    Chapman, Karen E.
    ENDOCRINOLOGY, 2010, 151 (01) : 195 - 202
  • [34] The discovery of 2-anilinothiazolones as 11β-HSD1 inhibitors
    Yuan, Chester
    St. Jean, David J., Jr.
    Liu, Qingyian
    Cai, Lynn
    Li, Aiwen
    Han, Nianhe
    Moniz, George
    Askew, Ben
    Hungate, Randall W.
    Johansson, Lars
    Tedenborg, Lars
    Pyring, David
    Williams, Meredith
    Hale, Clarence
    Chen, Michelle
    Cupples, Rod
    Zhang, Jiandong
    Jordan, Steven
    Bartberger, Michael D.
    Sun, Yaxiong
    Emery, Maurice
    Wang, Minghan
    Fotsch, Christopher
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (22) : 6056 - 6061
  • [35] Discovery of orally active butyrolactam 11β-HSD1 inhibitors
    Yeh, Vince S. C.
    Kurukulasuriya, Ravi
    Fung, Steven
    Monzon, Katina
    Chiou, William
    Wang, Jiahong
    Stolarik, Deanne
    Imade, Hovis
    Shapiro, Robin
    Knourek-Segel, Victoria
    Bush, Eugene
    Wilcox, Denise
    Nguyen, Phong T.
    Brune, Michael
    Jacobson, Peer
    Link, J. T.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (21) : 5555 - 5560
  • [36] Comparison of a homology model and the crystallographic structure of human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) in a structure-based identification of inhibitors
    Laurence Miguet
    Ziding Zhang
    Maryse Barbier
    Martin G. Grigorov
    Journal of Computer-Aided Molecular Design, 2006, 20 : 67 - 81
  • [37] Comparison of a homology model and the crystallographic structure of human 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) in a structure-based identification of inhibitors
    Miguet, Laurence
    Zhang, Ziding
    Barbier, Maryse
    Grigorov, Martin G.
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2006, 20 (02) : 67 - 81
  • [38] Identification and optimisation of 3,3-dimethylazetidin-2-ones as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1)
    McCoull, William
    Augustin, Martin
    Blake, Caroline
    Ertan, Anne
    Kilgour, Elaine
    Krapp, Stephan
    Moore, Jane E.
    Newcombe, Nicholas J.
    Packer, Martin J.
    Rees, Amanda
    Revill, John
    Scott, James S.
    Selmi, Nidhal
    Gerhardt, Stefan
    Ogg, Derek J.
    Steinbacher, Stefan
    Whittamore, Paul R. O.
    MEDCHEMCOMM, 2014, 5 (01) : 57 - 63
  • [39] Development of 11β-HSD1 inhibitors for the treatment of type 2 diabetes
    Hale, Clarence
    Wang, Minghan
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (07) : 702 - 710
  • [40] Atheroprotection Induced by Selective 11β-Hydroxysteroid Dehydrogenase Type 1 (11βHSD1) Inhibition in Male ApoE-/-Mice
    Huebschle, Thomas
    Falk, Eugen
    Glien, Maike
    Sadowski, Thorsten
    Ruetten, Hartmut
    DIABETES, 2011, 60 : A105 - A105
12345